Universal reference book for medicines
Name of the drug: UZARA ® (UZARA)

Active substance: nonappropriate

Type: Antidiarrhoeal phytopreparation

Manufacturer: STADA Arzneimittel (Germany) manufactured by ROTTENDORF PHARMA (Germany)
Composition, form of production and packaging
The tablets covered with a cover of
white color, round, biconcave;
the core of the tablet is from light brown to brown with white impregnations.
1 ml

dry extract of the root of Uzara (4-6: 1) (in terms of Uzarin) 40 mg

Auxiliary substances: wheat starch, lactose monohydrate, starch from locust bean seeds, talc, silicon dioxide colloidal anhydrous, magnesium stearate.

The composition of the tablet shell: calcium carbonate, glucose syrup (dry matter), magnesium oxide, corn starch (Snowflake 06598), castor oil, sucrose, shellac, talc, titanium dioxide E171, mountain glycine wax.

10 pieces.
- packings cellular planimetric (2) - packs cardboard.
10 pieces.
- packings cellular planimetric (5) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2014.

PHARMACHOLOGIC EFFECT

The antidiarrhoeal effect of the drug Uzara ® is associated with the stimulation of the glycosides (active ingredients of Uzara ® ) of the sympathetic nervous system, as a result of which the motility of the intestine is weakened and the stool is normalized.

In addition to suppressing the motility of the digestive tract, the active substances of Uzara ® have antispasmodic, antisecretory, astringent and enveloping effects.

INDICATIONS

- nonspecific acute diarrhea.

DOSING MODE

Inside, regardless of food intake.

Adults and children over 12 years of age: the initial dose on the first day - 5 tablets (200 mg) once, in the following days - 1 tablet (40 mg) 3-6 times a day before the normalization of the stool.
It is recommended to drink tablets with a small amount of liquid.
SIDE EFFECT

Allergic reactions.

CONTRAINDICATIONS

hypersensitivity to the components of the drug;

- simultaneous reception of cardiac glycosides;

- Alcoholism;

- Children's age (up to 12 years).

PREGNANCY AND LACTATION

In experimental studies, there were no teratogenic, mutagenic properties of Uzara ® .
Until now, there have been no reports of any developmental defects in the use of the drug. Since the clinical experience of using the drug in pregnant and lactating women is very limited, the Uzara ® drug should be used only according to strict indications, when the prospective benefit to the mother exceeds the potential risk for the fetus and the baby.
APPLICATION FOR CHILDREN

Contraindicated for children under 12 years.

SPECIAL INSTRUCTIONS

If the duration of diarrhea exceeds 2 days, it is accompanied by high body temperature, and if there are impurities in the stool, you should immediately consult a doctor.

DRUG INTERACTION

With simultaneous use with drugs quinidine, calcium, diuretics (saluretics) or long-term therapy with cortisone drugs, there may be violations of the heart rhythm.

TERMS OF RELEASE FROM PHARMACY

On prescription.

TERMS AND CONDITIONS OF STORAGE

At a temperature of no higher than 25 ° C.
In a place inaccessible to children. Shelf life - 3 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!